ML20205C882

From kanterella
Jump to navigation Jump to search
Forwards Abbreviated Summary of Approved Radiopharm Drug Products, Per 860327 Request Re Glofil-125. Licensees Authorized for Groups I & II May Use Glofil-125 as Group I Procedure But Not as Group II Procedure.W/O Encl
ML20205C882
Person / Time
Issue date: 08/01/1986
From: Whiston P
NRC OFFICE OF INSPECTION & ENFORCEMENT (IE REGION III)
To: Mason T
MEDICAL PHYSICS CONSULTANTS, INC.
Shared Package
ML20205C889 List:
References
NUDOCS 8608140479
Download: ML20205C882 (1)


Text

- - _.

AUG 1 1986 Medical Physics Consultants, Inc.

ATTN: Tony R. Mason, M.S.

Medical Radiation Physicist 3200 West Liberty Suite F1 Ann Arbor, MI 48103 Gentlemen:

Enclosed is an April 1,1981 copy of an " Abbreviated Summary of Approved Radiopharmaceutical Drug Products" which contains the Isotex product "Glofil-125" (see Item 14 of enclosure) referenced in your March 27, 1986 letter. This product can be used by Group I licensees.

Please refer to 10 CFR Part 35, Section 35.100, Scheduled A, Item (a)(2) which lists iodine-125 as sodium iothalamate (Glofil-125) for diagnostic studies involving measurements of uptake dilution and excretion (e.g., glomerular filtration rate).

Pleasealsonotethat10CFRPart35,Section35.100,ScheduleA, Item (b)(2) lists iodine-125 as sodium iodide or fibrinogen to be used for diagnostic imaging and localization. Therefore, licensees' authorized for Groups I and II may use the "Glofil-125" as a Group I procedure, not a Group II procedure.

If you have any questions or require clarification on any of the information stated above, you may contact us at (312) 790-5625.

Sincerely, Patricia J. Whiston Materials Licensing Section

Enclosures:

1.

Abbreviated Sumary of Approved Radiopharmaceutical Drug Projects 2.

10 CFR Part 35 R II d

\\

c ston/jl N!0 8608140479 860801 REG 3 LIC30